Insider Selling: Cencora, Inc. (NYSE:COR) CEO Sells 10,754 Shares of Stock

Cencora, Inc. (NYSE:COR) CEO Steven H. Collis sold 10,754 shares of the stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $237.48, for a total value of $2,553,859.92. Following the completion of the transaction, the chief executive officer now directly owns 285,088 shares in the company, valued at approximately $67,702,698.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Cencora Stock Down 0.6 %

Shares of NYSE COR opened at $237.30 on Friday. The company has a current ratio of 0.88, a quick ratio of 0.52 and a debt-to-equity ratio of 3.94. The stock has a market capitalization of $47.34 billion, a PE ratio of 25.85, a price-to-earnings-growth ratio of 1.82 and a beta of 0.45. The stock’s fifty day simple moving average is $237.53 and its two-hundred day simple moving average is $214.64. Cencora, Inc. has a 12-month low of $163.37 and a 12-month high of $246.75.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $3.28 earnings per share for the quarter, topping analysts’ consensus estimates of $2.86 by $0.42. The firm had revenue of $72.25 billion during the quarter, compared to analysts’ expectations of $68.81 billion. Cencora had a return on equity of 323.23% and a net margin of 0.69%. During the same quarter last year, the firm earned $2.71 EPS. As a group, analysts expect that Cencora, Inc. will post 13.43 EPS for the current fiscal year.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, February 26th. Stockholders of record on Friday, February 9th were given a $0.51 dividend. This is a boost from Cencora’s previous quarterly dividend of $0.24. The ex-dividend date was Thursday, February 8th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.86%. Cencora’s dividend payout ratio (DPR) is presently 22.22%.

Institutional Trading of Cencora

Institutional investors have recently made changes to their positions in the business. Martin Capital Partners LLC acquired a new stake in shares of Cencora in the 1st quarter worth $1,009,000. Boltwood Capital Management acquired a new stake in Cencora during the 1st quarter worth about $432,000. Vanguard Group Inc. acquired a new stake in Cencora during the 4th quarter worth about $4,212,508,000. Park National Corp OH acquired a new stake in Cencora during the 1st quarter worth about $5,947,000. Finally, Symmetry Partners LLC acquired a new stake in Cencora during the 1st quarter worth about $1,860,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on COR shares. Barclays started coverage on Cencora in a research note on Wednesday, January 3rd. They issued an “overweight” rating and a $242.00 price objective on the stock. Mizuho increased their price objective on Cencora from $192.00 to $224.00 and gave the stock a “neutral” rating in a research note on Monday, February 5th. SVB Leerink started coverage on Cencora in a research note on Monday, February 26th. They issued an “outperform” rating and a $261.00 price objective on the stock. Leerink Partnrs reissued an “outperform” rating on shares of Cencora in a research note on Monday, February 26th. Finally, StockNews.com raised Cencora from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 1st. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $218.22.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.